New Stock News | Gao Guang Pharmaceuticals submitted application to Hong Kong Stock Exchange.

According to the disclosure on December 4th by the Hong Kong Stock Exchange, Hangzhou Gaoguang Pharmaceutical Co., Ltd. (hereinafter referred to as "Gaoguang Pharmaceutical") has submitted its application to the Main Board of the Hong Kong Stock Exchange, with CICC and CMB International as its joint sponsors. According to the prospectus, Gaoguang Pharmaceutical is a key innovative enterprise dedicated to exploring and developing safe and effective therapies for global patients with autoimmune/inflammatory diseases, and has established a unique advantage in the challenging field of neuroinflammation with world-class candidate drugs for the treatment of Alzheimer's and Parkinson's diseases. With end-to-end internal capabilities ranging from target selection, candidate drug discovery to clinical development, the company has built a differentiated asset portfolio (covering various autoimmune and neurodegenerative disease indications), including four candidates in clinical stage and multiple candidates in preclinical stage. The company's core product TLL-018, along with TLL-041 and TLL-009, are the only highly selective TYK2/JAK1 inhibitors in the world. TLL-018 is expected to become the first-in-class and best-in-class therapy for chronic spontaneous urticaria (CSU) and rheumatoid arthritis (RA). The company is currently conducting two Phase III registration trials for CSU and RA in China, and plans to submit NDA to the National Medical Products Administration by the end of 2026.